文献速递类风湿关节炎

日本类风湿关节炎分子靶向治疗临床缓解率的变迁:来自FIRST登记研究的启示

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究基于日本FIRST登记研究2916例类风湿关节炎患者,分析2003至2022年生物/靶向合成改善病情抗风湿药(b/tsDMARDs)启用1年后的临床缓解率每两年变化。临床疾病活动指数(CDAI)缓解率从2003年至2013年持续上升,2013年达峰后下降,至2021年回落至2009年水平;多因素分析显示甲氨蝶呤(MTX)≥10 mg/周、未联用糖皮质激素、低疾病活动度、低HAQ残疾指数评分及使用Janus激酶(JAK)抑制剂与1年后CDAI缓解相关。

要点

  • CDAI缓解率2003至2013年持续上升,2013年达峰后下降,2021年回落至2009年水平。
  • 1年后CDAI缓解的相关因素包括MTX≥10 mg/周、未联用糖皮质激素、低疾病活动度、低HAQ残疾指数评分及使用JAK抑制剂。
  • 2011年以来MTX使用下降且平均血清肌酐升高,2021年以来JAK抑制剂使用快速减少。

核心结论

  • 尽管治疗和早期干预策略不断进步,类风湿关节炎的临床缓解率并未持续改善,原因包括MTX使用减少。

研究设计与样本

  • 基于日本FIRST登记研究的分析,纳入2916例类风湿关节炎患者,分析2003至2022年患者背景及b/tsDMARDs启用1年后临床缓解率的每两年变化,并探讨缓解的决定因素。

主要发现

  • 随时间推移患者平均年龄增加、b/tsDMARDs启用更早、MTX联用率存在波动。
  • CDAI缓解率从2003年至2013年持续上升,2013年达峰后下降,至2021年回落至2009年水平。
  • 多因素分析显示,1年后CDAI缓解的相关因素包括MTX剂量≥10 mg/周、未联用糖皮质激素、低疾病活动度、低HAQ残疾指数评分及使用JAK抑制剂。
  • 自2011年以来MTX使用下降且平均血清肌酐水平升高,自2021年以来JAK抑制剂使用快速减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate the prevailing concerns by analysing the shifts in clinical profiles and therapeutic outcomes of patients with RA from 2003 to 2022, and offer guidelines to refine future treatment approaches. METHODS: Utilizing our registry data, we conducted an analysis of the patient background and biennial variations in the clinical remission rate 1 year post-initiation of biological/targeted synthetic DMARDs (b/tsDMARDs) in patients with RA in Phase II. We investigated the determinants of remission. RESULTS: This study registered 2916 patients. Over time, the patient demographics evolved, characterized by an increase in the average age of patients, earlier initiation of b/tsDMARDs, and variability in the rate of concomitant use of MTX. The remission rate, as measured by the Clinical Disease Activity Index (CDAI), consistently rose from 2003 to 2013, then declined after reaching its peak in 2013. By 2021, it had returned to the same level observed in 2009. The findings of the multivariate analysis indicated that the factors contributing to CDAI remission after 1 year included the administration of MTX at a dosage of 10 mg/week or higher, the absence of concomitant glucocorticoid use, low disease activity, a low HAQ Disability Index score, and the utilization of Janus kinase (JAK) inhibitors. Specifically, since 2011, the use of MTX has declined alongside rising average serum creatinine levels. Additionally, the utilization of JAK inhibitors has rapidly decreased since 2021. CONCLUSION: Despite advancements in treatment and early intervention strategies, the clinical remission rate for RA has not shown consistent improvement. Factors contributing to this include reduced use of MTX.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kubo S, Miyazaki Y, Tanaka H, et al. Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry. Rheumatology (Oxford). 2025. PMID: 40358556. doi:10.1093/rheumatology/keaf246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。